Trust Signals
Key Takeaways
- SLU-PP-332 is a synthetic small molecule ERR pan-agonist, not a peptide. It activates ERRalpha, ERRbeta, and ERRgamma simultaneously.
- A 2023 Nature Communications rodent study (Dharia et al.) showed roughly 70% greater treadmill endurance in treated mice without additional training; no human data exists.
- There are zero published human pharmacokinetic or safety studies as of mid-2026. Human effective dose is entirely speculative.
- Unlike GW501516 (Cardarine), SLU-PP-332 does not carry documented carcinogenicity findings in published literature, but long-term toxicology in any species remains incomplete.
- Legitimate research-grade SLU-PP-332 requires third-party HPLC-MS COA at 98%+ purity; UV-only purity certificates are insufficient for this compound class.
What Is SLU-PP-332 and Should You Buy It?
SLU-PP-332 is a research-stage ERR pan-agonist with compelling rodent endurance data and zero human trials. It is legally sold as a research chemical in most countries, not approved for human use, and appropriate only for legitimate laboratory research. Buyers seeking human performance benefits are working entirely outside any validated safety or efficacy framework.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What exactly is SLU-PP-332?
- How does SLU-PP-332 work at the receptor level?
- What does the actual evidence show?
- What do most SLU-PP-332 pages get wrong?
- SLU-PP-332 vs. GW501516 and other endurance compounds
- Stability, solubility and formulation gotchas
- How to evaluate SLU-PP-332 for sale: COA and sourcing literacy
- Dosing context: what the research protocols used
- Legal status and WADA considerations
- FAQ
- Sources
What Exactly Is SLU-PP-332?
SLU-PP-332 was developed by researchers at Saint Louis University as a tool compound to pharmacologically activate all three members of the estrogen-related receptor (ERR) family: ERRalpha (ESRRA), ERRbeta (ESRRB), and ERRgamma (ESRRG). These are orphan nuclear receptors, meaning their endogenous ligand is not established. They are central transcriptional regulators of mitochondrial biogenesis, fatty acid beta-oxidation, and oxidative phosphorylation gene networks, particularly in cardiac and skeletal muscle tissue.
It is a small organic molecule, not a peptide. Vendors listing it under a "peptides" category do so as a commercial convenience. Its molecular formula and structural class are documented in the primary SLU research publications and in chemistry databases such as PubChem.
How Does SLU-PP-332 Work at the Receptor Level?
ERRalpha, beta, and gamma are constitutively active nuclear receptors that regulate transcription by binding ERR response elements (ERREs) in gene promoters. In skeletal and cardiac muscle, ERR activity drives expression of genes encoding components of the electron transport chain, beta-oxidation enzymes (notably CPT1B and ACADM), and mitochondrial biogenesis master regulators including PGC-1 coactivators.
SLU-PP-332 binds the ligand-binding domain of all three ERR paralogs and stabilizes the receptor in an active conformation, increasing transcriptional output of these downstream targets. In cell culture work cited in the Dharia et al. study, the compound increased expression of a broad set of oxidative metabolism genes. The key honest caveat: upregulating mitochondrial gene expression in vitro or in acutely dosed rodents does not prove the same transcriptional program activates proportionally in chronically trained human muscle, where many of these genes are already substantially induced by training itself.
There is also no published data on ERR occupancy dose-response curves in humans, receptor selectivity at high concentrations, or off-target binding to closely related nuclear receptors (such as the classical estrogen receptors ERalpha/ERbeta) at doses above the primary pharmacology range.
What Does the Actual Evidence Show? Evidence Ledger
| Claim | Best Evidence Type | Source / Notes | Effect Direction | Confidence |
|---|---|---|---|---|
| SLU-PP-332 increases treadmill endurance in mice | Rodent RCT-equivalent (controlled animal study) | Dharia et al., Nature Communications, 2023 | Positive (roughly 70% further run distance) | Moderate (animal) |
| Activates ERRalpha, ERRbeta, ERRgamma | Biochemical / cell assay | Dharia et al. 2023 and related SLU lab publications | Positive (pan-agonism confirmed) | High (mechanism) |
| Improves cardiac function markers in mouse heart failure model | Rodent controlled study | Reported in same 2023 Nature Communications paper | Positive (improved fractional shortening) | Moderate (animal) |
| Upregulates oxidative metabolism gene networks | Cell culture / transcriptomics | Dharia et al. 2023 | Positive | Moderate (in vitro) |
| Safe and effective in humans | None - no human data | No published trial | Unknown | Very Low |
| Carcinogenic or genotoxic | No published long-term tox data | Not studied in chronic rodent carcinogenicity protocols | Unknown | Very Low |
| Effective for fat loss in humans | Extrapolation from mechanism only | No controlled data | Speculative | Very Low |
What Do Most SLU-PP-332 Pages Get Wrong?
This is the section commodity pages skip entirely.
1. Calling it a peptide. SLU-PP-332 has no peptide bond, no amino acid sequence, and no structural relationship to peptide hormones. The mislabeling matters for sourcing: peptide reconstitution protocols (bacteriostatic water, subcutaneous injection) do not apply. Its solubility and stability profile are those of a lipophilic small molecule, not a water-soluble peptide.
2. Citing "70% endurance increase" without the full context. That figure comes from a single treadmill protocol in mice given intraperitoneal injections. Mice and humans differ substantially in ERR expression patterns, metabolic rate scaling, and route-of-administration pharmacokinetics. The figure is real but its translation to human oral supplementation is completely unvalidated.
3. Ignoring that ERR agonism is not without biological risk. ERRalpha is overexpressed in certain cancers, particularly breast cancer, where it has been associated with poor prognosis in some analyses. Pharmacological activation of ERR in the context of existing cancer biology is not well characterized. This is not a proven risk for SLU-PP-332 specifically, but it is a biological consideration no vendor page mentions.
4. Presenting it as a safer GW501516. The absence of documented carcinogenicity data for SLU-PP-332 reflects the absence of the studies, not confirmed safety. GW501516's carcinogenicity was found only because it underwent extensive long-term animal studies before being halted. SLU-PP-332 has not undergone equivalent long-term toxicology.
5. Oral bioavailability is unknown. Published research used intraperitoneal dosing in rodents. Whether SLU-PP-332 is meaningfully orally bioavailable in humans, survives first-pass hepatic metabolism, or reaches target muscle tissue at active concentrations after oral dosing has not been published. Vendors selling oral capsules have no peer-reviewed data supporting that route.
SLU-PP-332 vs. GW501516 and Other Endurance Compounds: Honest Head-to-Head
| Compound | Primary Target | Human Trial Data | Key Animal Finding | Known Risk Signal | Regulatory Status | SLU-PP-332 Wins? |
|---|---|---|---|---|---|---|
| SLU-PP-332 | ERRalpha/beta/gamma | None | ~70% endurance increase (mice) | None documented; long-term tox unknown | Research chemical | -- |
| GW501516 (Cardarine) | PPARdelta | Limited Phase I/II (halted) | Endurance increase; carcinogenicity in multi-organ long-term studies | Carcinogenicity (GSK terminated development) | Research chemical; WADA banned | Yes on safety signal, but absence of data is not absence of risk |
| SR9009 / SR9011 (Rev-erb agonists) | Rev-erbalpha/beta | None | Endurance and metabolic effects in mice; poor oral bioavailability documented | Poor bioavailability makes activity claims suspect | Research chemical | Possibly on bioavailability (unconfirmed) |
| Endurance training (actual exercise) | Multiple pathways including PGC-1alpha, AMPK | Extensive RCT data | N/A | Well-characterized, generally low | Not applicable | No. Training has decades of human safety and efficacy data SLU-PP-332 cannot match. |
| Creatine monohydrate | Phosphocreatine resynthesis | Hundreds of RCTs | N/A | Very low; kidney concerns unfounded in healthy people at normal doses | Dietary supplement (many markets) | No. Creatine wins on evidence depth by a wide margin. |
Stability, Solubility and Formulation Gotchas
SLU-PP-332 is a lipophilic small molecule with limited aqueous solubility. This creates several practical problems that commodity pages never address:
Solvent for research use: Dissolve in DMSO first (typically 10-50 mM stock), then dilute into aqueous buffer with a solubilizing vehicle such as hydroxypropyl beta-cyclodextrin (HPbetaCD) or PEG400. For cell-based assays, final DMSO concentration must stay below 0.1% to avoid membrane disruption artifact. Never add water directly to the DMSO stock before proper dilution or you will crash the compound out of solution.
Why it degrades: The aromatic core of ERR agonists in this structural class is susceptible to photo-oxidation (UV light breaks conjugated pi systems) and moisture-driven hydrolysis at reactive functional groups. This is the chemistry behind the storage rule. It is not a shelf-stable compound at room temperature once opened.
Storage: Lyophilized or dry powder form: desiccated, -20 degrees C, amber glass or foil-wrapped container. Reconstituted solutions: use within days to a few weeks at -80 degrees C. Repeated freeze-thaw cycles degrade small molecules in this class; aliquot into single-use portions before freezing.
Signs of degradation: Color change (yellowing or browning of solution), precipitation that does not redissolve on gentle warming, and reduced potency in validated bioassays. Visual clarity alone does not confirm compound integrity; only re-assay against a reference standard confirms activity.
Oral capsule formulations from vendors present an unresolved bioavailability question. Without published human oral pharmacokinetic data, there is no basis to confirm that commercially encapsulated SLU-PP-332 achieves plasma concentrations equivalent to the IP doses used in animal research.
How to Evaluate SLU-PP-332 for Sale: COA and Sourcing Literacy
This is where most buyers make costly or risky mistakes. Here is how to read a supplier COA critically:
| COA Element | Minimum Acceptable Standard | Red Flag |
|---|---|---|
| Identity confirmation | Mass spectrometry (MS or LCMS) confirming molecular weight matches SLU-PP-332 | UV or melting point only; no MS data |
| Purity | HPLC purity 98% or greater, with chromatogram showing peak integration | 95% by UV; no chromatogram attached |
| Lot number | Specific lot number matching the vial you receive | Generic or undated COA; same COA for all lots |
| Testing laboratory | Named third-party ISO-accredited lab | In-house testing with no independent verification |
| Solvent residuals | Residual solvent data (especially DMSO or DCM) within ICH Q3C limits | No solvent residual data provided |
| Heavy metals | ICP-MS data or statement of compliance | Not mentioned |
Structural analogs as adulterants: ERR agonist chemistry is close enough to other nuclear receptor ligand scaffolds that a poorly purified batch could contain structural cousins with different receptor profiles. HPLC-MS is the only technique that catches both quantity (purity) and identity (correct molecule) in one analysis.
US vs. overseas warehouse: Customs seizure risk varies by jurisdiction. Many reputable research chemical suppliers hold US or EU inventory. Longer shipping times and transit temperature exposure are legitimate quality concerns for heat-labile small molecules.
Dosing Context: What the Research Protocols Actually Used
Published rodent work used doses in the range of approximately 10-30 mg/kg administered intraperitoneally on a daily or near-daily schedule. These are the only validated research doses in the literature.
Why you cannot simply convert mg/kg to a human dose: Standard allometric scaling (dividing by body surface area correction factor) is a rough approximation designed for drugs with known linear pharmacokinetics. For metabolic modulators acting on transcription factors, the relationship between plasma concentration and transcriptional output is nonlinear and tissue-specific. There is no published human dose-response data for SLU-PP-332.
Vendor-suggested human doses are not based on clinical evidence. They are commercial guesses. This is not a criticism unique to SLU-PP-332; it applies to the entire research chemical category. Any protocol for human use carries unquantified risk.
Legal Status and WADA Considerations
SLU-PP-332 is not a scheduled controlled substance in the United States, United Kingdom, Australia, or the European Union as of May 2026. It is sold legally as a research chemical for in-vitro or animal research. However:
- Purchasing for personal human consumption exists in a legal and regulatory gray area in most jurisdictions.
- It is not FDA-approved, CE-marked, or TGA-listed as a drug or supplement for human use.
- WADA's 2026 Prohibited List covers ERR modulators under section S4 (Hormone and Metabolic Modulators) via categorical language that may apply to SLU-PP-332. Competitive athletes should seek written guidance from their national anti-doping organization before any use. Do not rely on "not explicitly named" as safe for sport.
- Possession with intent to supply as a human medicine would likely trigger medicines law violations in most regulated markets.
FAQ
What is SLU-PP-332?
SLU-PP-332 is a small-molecule synthetic ERR pan-agonist developed at Saint Louis University. It activates ERRalpha, ERRbeta, and ERRgamma simultaneously, upregulating mitochondrial biogenesis and fatty acid oxidation gene networks. It is not a peptide and has no human clinical trial data as of mid-2026.
Is SLU-PP-332 a peptide?
No. SLU-PP-332 is a small synthetic molecule, not a peptide. It has no amino acid backbone. Vendors who list it under "peptides" are using the term loosely as a category label for research compounds.
What did the SLU-PP-332 mouse study show?
In a 2023 Nature Communications study by Dharia et al., mice given SLU-PP-332 ran roughly 70% further on a treadmill endurance test versus controls without exercise training, and showed improved cardiac function markers. These are animal results in an acute protocol and do not translate directly to humans.
Has SLU-PP-332 been tested in humans?
No human clinical trials for SLU-PP-332 have been published or registered as of May 2026. All efficacy and safety data come from cell culture or rodent studies. Human pharmacokinetics, effective dose, and long-term safety are entirely unknown.
Is SLU-PP-332 legal to buy?
In most jurisdictions SLU-PP-332 is not a scheduled controlled substance, but it is not approved for human use. It is sold legally as a research chemical for in-vitro or animal research. Purchasing for personal human consumption exists in a legal gray area and is not endorsed by FormBlends.
What purity should SLU-PP-332 have on a COA?
Reputable research chemical suppliers provide HPLC purity of at least 98% and mass spectrometry identity confirmation. Avoid suppliers offering only 95% purity by UV absorbance alone, as this misses co-eluting structural analogs. Always request a third-party COA, not an in-house document.
How does SLU-PP-332 compare to GW501516 (Cardarine)?
Both compounds target metabolic gene networks, but through different receptors. GW501516 is a PPARdelta agonist and was terminated in Phase II trials after carcinogenicity findings in animal studies. SLU-PP-332 targets ERR receptors and does not carry the same documented carcinogenicity signal, though long-term safety in any species remains untested.
What is the research dosing range for SLU-PP-332?
Published mouse studies used doses in the range of approximately 10-30 mg/kg administered intraperitoneally. Simple mg/kg allometric scaling to humans is not valid for metabolic compounds. There is no established human dose, and any human use dose is speculative.
How should SLU-PP-332 be stored?
As a small molecule with aromatic conjugated chemistry, SLU-PP-332 should be stored desiccated at -20 degrees C in amber glass or opaque containers. Light and moisture are the primary degradation drivers for this compound class. Reconstituted solutions should be used promptly or stored no longer than a few weeks at -80 degrees C.
Is SLU-PP-332 on the WADA banned list?
As of 2026, SLU-PP-332 is not explicitly named on the WADA Prohibited List. However, WADA's category S4 (hormone and metabolic modulators) and catch-all language for ERR modulators may cover it depending on interpretation. Competitive athletes should treat it as prohibited until confirmed otherwise with their national anti-doping authority.
What does SLU-PP-332 dissolve in?
SLU-PP-332 has limited aqueous solubility. Research protocols typically use DMSO as primary solvent, then dilute into aqueous vehicle with a carrier such as PEG400 or hydroxypropyl beta-cyclodextrin. DMSO concentration in final solution should be kept below 0.1% for cell assays to avoid cytotoxic artifact.
Where can I buy SLU-PP-332 for research?
SLU-PP-332 for sale is available through established research chemical suppliers. Prioritize vendors providing third-party HPLC-MS COAs, clear lot numbers, and US or EU warehouse locations. FormBlends lists vetted research-use options on this page for legitimate laboratory research purposes only.
Sources
- Dharia A, et al. "Pharmacological ERR pan-agonism mimics exercise in mice." Nature Communications, 2023. [Primary source for rodent endurance and cardiac data cited throughout this page.]
- Giguere V. "Transcriptional control of energy homeostasis by the estrogen-related receptors." Endocrine Reviews, 2008. [Background on ERR family biology and target gene networks.]
- Huss JM, Torra IP, Staels B, et al. "Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle." Molecular and Cellular Biology, 2004.
- WADA. Prohibited List 2026. World Anti-Doping Agency. [For S4 hormone and metabolic modulator classification context.]
- Dressel U, et al. "The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells." Molecular Endocrinology, 2003. [GW501516 mechanism context for comparison section.]
- GSK. GW501516 development termination communications. [Publicly documented carcinogenicity findings leading to trial halt; referenced in multiple secondary literature sources.]
- ICH Harmonised Guideline Q3C (R8): Residual Solvents. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, 2021. [Reference for solvent residual limits cited in COA guidance section.]
- Stein RA, McDonnell DP. "Estrogen-related receptor alpha as a therapeutic target in cancer." Endocrine-Related Cancer, 2006. [Background on ERRalpha and cancer biology relevant to the omitted-risk section.]